ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 14 2025
0mins
Source: Newsfilter
Diabetes and Kidney Damage: Research indicates that diabetes-related metabolic issues lead to lipid accumulation in kidneys, causing inflammation and fibrosis, which contribute to chronic kidney disease (CKD) progression.
ZyVersa's VAR 200 Development: ZyVersa Therapeutics is developing VAR 200, a treatment aimed at removing excess lipids from kidneys, with a Phase 2a clinical trial underway for diabetic kidney disease (DKD), highlighting the urgent need for therapies targeting kidney lipotoxicity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
